Early fecal microbiota transplantation improves survival in severe clostridium difficile infections

Clinical Infectious Diseases

Volumn 66, Issue 5, 2018, Pages 645-650

  Hocquart, Marie ^a,b   Lagier, Jean Christophe ^a   Cassir, Nadim ^a   Saidani, Nadia ^a   Eldin, Carole ^a   Kerbaj, Jad ^a   Delord, Marion ^a   Valles, Camille ^a   Brouqui, Philippe ^a   Raoult, Didier ^a   Million, Matthieu ^a,b  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Clostridium difficile; Fecal microbiota transplantation; Mortality; Survival; Treatment

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

AGED; ARTICLE; CHARLSON COMORBIDITY INDEX; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; FRANCE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY; CLOSTRIDIOIDES DIFFICILE; CLOSTRIDIUM INFECTION; FECES; HOSPITALIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MORTALITY; ODDS RATIO; PSEUDOMEMBRANOUS COLITIS; RECURRENT DISEASE; RIBOTYPING; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME TO TREATMENT;

AGED; AGED, 80 AND OVER; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; FECES; FEMALE; FRANCE; HOSPITALIZATION; HUMANS; MALE; ODDS RATIO; RECURRENCE; RETROSPECTIVE STUDIES; RIBOTYPING; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 85049119714     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix762     Document Type: Article

References (44)

1. Kurti Z, Lovasz BD, Mandel MD, et al. Burden of Clostridium difficile infection between 2010 and 2013: trends and outcomes from an academic center in Eastern Europe. World J Gastroenterol 2015; 21:6728–35.
2. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825–34.
3. Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M; Canadian Hospital Epidemiology Committee. Canadian Nosocomial Infection Surveillance Program. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002; 23:137–40.
4. Sailhamer EA, Carson K, Chang Y, et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 2009; 144:433–9; discussion 439–40.
5. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235:363–72.
6. Lamontagne F, Labbé AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007; 245:267–72.
7. Dudukgian H, Sie E, Gonzalez-Ruiz C, Etzioni DA, Kaiser AM. C. difficile colitis—predictors of fatal outcome. J Gastrointest Surg 2010; 14:315–22.
8. Bhangu A, Nepogodiev D, Gupta A, Torrance A, Singh P; West Midlands Research Collaborative. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg 2012; 99:1501–13.
9. Lagier JC, Dubourg G, Cassir N, et al. Clostridium difficile 027 emerging outbreak in Marseille, France. Infect Control Hosp Epidemiol 2013; 34:1339–41.
10. Lagier JC, Delord M, Million M, et al. Dramatic reduction in Clostridium difficile ribotype 027-associated mortality with early fecal transplantation by the nasogas-tric route: a preliminary report. Eur J Clin Microbiol Infect Dis 2015; 34:1597–601.
11. Barbut F, Decré D, Lalande V, et al. Clinical features of Clostridium difficile-as-sociated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol 2005; 54:181–5.
12. Kassam Z, Cribb Fabersunne C, Smith MB, et al. Clostridium difficile associated risk of death score (CARDS): a novel severity score to predict mortality among hospitalised patients with C. difficile infection. Aliment Pharmacol Ther 2016; 43:725–33.
13. Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20(suppl 2):1–26.
14. Johnson S, Louie TJ, Gerding DN, et al; Polymer Alternative for CDI Treatment (PACT) investigators. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014; 59:345–54.
15. Peláez T, Alcalá L, Alonso R, Rodríguez-Créixems M, García-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002; 46:1647–50.
16. Cornely OA, Crook DW, Esposito R, et al; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12:281–9.
17. Kokkotou E, Moss AC, Michos A, et al. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother 2008; 52:1121–6.
18. Johnson S, Louie TJ, Gerding DN, et al; Polymer Alternative for CDI Treatment (PACT) Investigators. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014; 59:345–54.
19. Musher DM, Logan N, Mehendiratta V, Melgarejo NA, Garud S, Hamill RJ. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007; 59:705–10.
20. McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006; 49:640–5.
21. Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA 2015; 313:1719–27.
22. van Kleef E, Deeny SR, Jit M, et al. The projected effectiveness of Clostridium difficile vaccination as part of an integrated infection control strategy. Vaccine 2016; 34:5562–70.
23. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407–15.
24. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015; 41:835–43.
25. Aroniadis OC, Brandt LJ, Greenberg A, et al. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol 2016; 50:398–402.
26. Zainah H, Hassan M, Shiekh-Sroujieh L, Hassan S, Alangaden G, Ramesh M. Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium difficile infection. Dig Dis Sci 2015; 60:181–5.
27. Million M, Hocquart M, Seghboyan JM, et al. Faecal microbiota transplantation as salvage therapy for fulminant Clostridium difficile infections. Int J Antimicrob Agents 2015; 46:227–8.
28. Fuentes S, van Nood E, Tims S, et al. Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection. ISME J 2014; 8:1621–33.
29. Shankar V, Hamilton MJ, Khoruts A, et al. Species and genus level resolution analysis of gut microbiota in Clostridium difficile patients following fecal microbiota transplantation. Microbiome 2014; 2:13.
30. Li YT, Cai HF, Wang ZH, Xu J, Fang JY. Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. Aliment Pharmacol Ther 2016; 43:445–57.
31. Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the literature. J Hosp Infect 2016; 92:117–27.
32. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107:1079–87.
33. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014; 312:1772–8.
34. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370:1453–7.
35. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373–83.
36. Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM). La transplantation de microbiote fécal et son encadrement dans les essais clin-iques [in French]. 2014. Available at: http://ansm.sante.fr/var/ansm_site/storage/original/application/5e5e01018303790194275ded0e02353c.pdf. Accessed 15 May 2017.
37. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442–9.
38. Million M, Raoult D. Reply to He et al. Clin Infect Dis 2014; 59:1347–8.
39. Byar DP, Schoenfeld DA, Green SB, et al. Design considerations for AIDS trials. N Engl J Med 1990; 323:1343–8.
40. Yazdanpanah Y, Horby P, van Griensven J, et al. Drug assessment in the Ebola virus disease epidemic in West Africa. Lancet Infect Dis 2015; 15:1258.
41. Atkins D, Best D, Briss PA, et al; GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328:1490.
42. Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 2003; 327:1459–61.
43. Lagier JC, Raoult D. Deadly infectious diseases such as Ebola: the parachute paradigm. Clin Microbiol Infect 2015; 21:389–90.
44. Brandt LJ, Borody TJ, Campbell J. Endoscopic fecal microbiota transplantation: “first-line” treatment for severe Clostridium difficile infection? J Clin Gastroenterol 2011; 45:655–7.